Carcinomas start in epithelial cells, the tissue that lines your organs and skin. Sarcomas start in mesenchymal cells, the tissue that forms bone, muscle, fat, and cartilage. That single difference in cell origin shapes nearly everything about how these two cancer types behave, where they show up, how they spread, and how they’re treated.
Carcinomas are far more common. They account for the vast majority of cancer diagnoses, including breast, lung, colon, and prostate cancers. Sarcomas represent roughly 0.8% of all cancers in the United States, making them comparatively rare.
Where Each Type Starts in the Body
Epithelial cells form the surfaces and linings of your body: skin, the inside of your lungs, the lining of your digestive tract, the ducts in your breast tissue, and the inner walls of organs like your bladder and kidneys. Because these cells are everywhere, carcinomas can develop in almost any organ. The most familiar cancers, including lung cancer, colorectal cancer, pancreatic cancer, and most skin cancers, are carcinomas.
Sarcomas arise from a completely different family of cells. Mesenchymal cells are the building blocks of your body’s structural and connective tissues. That includes bone, skeletal muscle, smooth muscle, fat, cartilage, tendons, and blood vessels. So a sarcoma might develop in the thigh muscle, the shinbone, the fat behind the abdomen, or the wall of the stomach. There are two broad categories: bone sarcomas and soft tissue sarcomas.
Common Subtypes You May Encounter
Carcinomas are classified by the specific type of epithelial cell involved. The most common subtypes include:
- Adenocarcinoma: starts in gland-forming cells, common in the breast, colon, lung, prostate, and pancreas
- Squamous cell carcinoma: starts in flat cells lining surfaces like the skin, throat, esophagus, and cervix
- Basal cell carcinoma: the most common skin cancer, arising from cells at the base of the outer skin layer
- Transitional cell carcinoma: develops in the stretchy lining of the bladder and urinary tract
Sarcomas have dozens of subtypes, each named for the tissue they resemble. The most common soft tissue types start in cartilage (chondrosarcoma) or muscle (rhabdomyosarcoma from skeletal muscle, leiomyosarcoma from smooth muscle). Liposarcoma develops from fat cells. Gastrointestinal stromal tumors arise in the muscle layer of the stomach or intestinal wall. Bone sarcomas include osteosarcoma and Ewing sarcoma.
How They Spread Differently
One of the most clinically significant differences between these two cancer types is the route they use to spread. Carcinomas typically metastasize first through the lymphatic system, traveling to nearby lymph nodes before reaching distant organs. This is why lymph node biopsies are a standard part of staging for breast, lung, and many other carcinomas.
Most sarcomas skip the lymph nodes entirely. Instead, they spread through the bloodstream, a process called hematogenous metastasis. The lungs act as a filter for venous blood flow, which is why the lung is the most common site of distant spread for sarcomas. This difference in behavior changes how doctors monitor and stage each cancer type. A sarcoma patient is more likely to get regular chest imaging to watch for lung metastases, while a carcinoma patient may undergo lymph node evaluation as a priority.
Age and Risk Factors
Carcinomas are overwhelmingly diseases of aging. Most are diagnosed in people over 50, and well-established lifestyle and environmental risk factors play a major role: smoking, alcohol use, UV exposure, obesity, and chronic infections like HPV or hepatitis. These exposures accumulate over decades, which is why carcinoma risk climbs with age.
Sarcomas affect a broader age range and are among the top five causes of cancer death in people under 20. The median age at diagnosis for all sarcomas is 58, but certain subtypes skew dramatically younger. Rhabdomyosarcoma has a median diagnosis age of 17. Ewing sarcoma’s median is 18, and osteosarcoma’s is 22. For many sarcomas, the cause is unknown. Known risk factors include prior radiation therapy and certain inherited genetic conditions like Li-Fraumeni syndrome, which involves a mutation in a key tumor-suppressing gene. Some chemical exposures also increase risk, but unlike carcinomas, sarcomas have few links to common lifestyle factors.
Diagnosis Under the Microscope
When a pathologist examines a biopsy, the first step is often determining whether a tumor is epithelial (carcinoma) or mesenchymal (sarcoma). They do this using protein staining techniques. Epithelial cells produce a protein called cytokeratin, an internal structural fiber found in essentially all epithelial tissues. Mesenchymal cells instead produce vimentin, a different structural protein present in nearly all sarcomas. By staining tissue samples for these two markers, pathologists can usually sort a tumor into the correct category early in the diagnostic process.
From there, additional markers narrow the diagnosis to a specific subtype. This distinction matters because treatment plans for a carcinoma and a sarcoma found in the same area of the body can be completely different.
Treatment Differences
Both carcinomas and sarcomas are treated with surgery, radiation, and systemic therapies, but the emphasis and approach differ significantly.
Surgery for sarcomas centers on achieving clear margins, meaning removing the tumor with a surrounding cuff of healthy tissue to reduce the chance of recurrence. In extremity sarcomas (those in the arms or legs), this can be a balancing act between removing enough tissue and preserving limb function. When the margin is very close or microscopically positive, radiation therapy before or after surgery is typically added. The goal is limb-salvage surgery whenever possible.
Carcinomas are also treated surgically, but because they commonly spread to lymph nodes, the surgical plan often includes lymph node sampling or removal. Many carcinomas respond well to chemotherapy and, increasingly, to targeted therapies and immunotherapies designed to exploit specific molecular features of epithelial tumors. Sarcomas generally respond less predictably to standard chemotherapy, and treatment plans are often highly specific to the sarcoma subtype.
Survival Rates and Outlook
Survival statistics vary enormously within both groups depending on the specific subtype and how early the cancer is caught. For soft tissue sarcomas found before they spread, the five-year survival rate is about 83%, and ten-year survival rates are similar, suggesting that people who reach the five-year mark are likely cured. Bone sarcomas caught early have five-year survival rates between 76% and 91%.
Carcinoma survival rates span an even wider range. Localized prostate and thyroid carcinomas have near-100% five-year survival, while pancreatic adenocarcinoma remains below 15%. The stage at diagnosis is the single biggest factor for both cancer families. A localized sarcoma and a localized carcinoma both carry far better outcomes than their metastatic counterparts, which is why the specific subtype and stage matter more than whether a cancer is labeled “carcinoma” or “sarcoma” when estimating an individual’s prognosis.